LupusTrials.org CATEGORIES: General SLE
First posted November 17, 2021, Updated September 9, 2022; Recruiting
The main purpose of this study is to assess the efficacy and safety of LY3361237 in participants with at least moderately active systemic lupus erythematosus (SLE). Study will last up to 34 weeks and may include up to 15 visits.
To Learn More Contact
Study Director at 1-877-CTLILLY or 1-317-615-4559 M-F 9 AM – 5 PM Eastern Time
ClinicalTrials.gov identifier (NCT number): NCT0513586